The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmaceutical Intermediate CDMO Market Research Report 2025
Synopsis
Global Pharmaceutical Intermediate CDMO market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical Intermediate CDMO market research.
Key companies engaged in the Pharmaceutical Intermediate CDMO industry include Cambrex, WR Grace, Esteve Química, AGC Pharma Chemicals, Evonik, CordenPharma, Otsuka Chemical, Wavelength and KBI Biopharma, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pharmaceutical Intermediate CDMO were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmaceutical Intermediate CDMO market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmaceutical Intermediate CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Cambrex
WR Grace
Esteve Química
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi'an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Segment by Type
Small Molecule Cdmo
Macromolecular Cdmo
Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical Intermediate CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Pharmaceutical Intermediate CDMO market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical Intermediate CDMO market research.
Key companies engaged in the Pharmaceutical Intermediate CDMO industry include Cambrex, WR Grace, Esteve Química, AGC Pharma Chemicals, Evonik, CordenPharma, Otsuka Chemical, Wavelength and KBI Biopharma, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pharmaceutical Intermediate CDMO were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmaceutical Intermediate CDMO market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmaceutical Intermediate CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Cambrex
WR Grace
Esteve Química
AGC Pharma Chemicals
Evonik
CordenPharma
Otsuka Chemical
Wavelength
KBI Biopharma
Chengda Pharmaceuticals
Apeloa Pharmaceutical
Xi'an Manareco New Materials
Shenzhen Sungening Bio-technology
Chengdu D-innovation Pharmaceutical
Huateng Pharma
Segment by Type
Small Molecule Cdmo
Macromolecular Cdmo
Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical Intermediate CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical Intermediate CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule Cdmo
1.2.3 Macromolecular Cdmo
1.3 Market by Application
1.3.1 Global Pharmaceutical Intermediate CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical Intermediate CDMO Market Perspective (2018-2029)
2.2 Pharmaceutical Intermediate CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical Intermediate CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceutical Intermediate CDMO Historic Market Size by Region (2018-2023)
2.2.3 Pharmaceutical Intermediate CDMO Forecasted Market Size by Region (2024-2029)
2.3 Pharmaceutical Intermediate CDMO Market Dynamics
2.3.1 Pharmaceutical Intermediate CDMO Industry Trends
2.3.2 Pharmaceutical Intermediate CDMO Market Drivers
2.3.3 Pharmaceutical Intermediate CDMO Market Challenges
2.3.4 Pharmaceutical Intermediate CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical Intermediate CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical Intermediate CDMO Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical Intermediate CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical Intermediate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical Intermediate CDMO Revenue
3.4 Global Pharmaceutical Intermediate CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical Intermediate CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical Intermediate CDMO Revenue in 2022
3.5 Pharmaceutical Intermediate CDMO Key Players Head office and Area Served
3.6 Key Players Pharmaceutical Intermediate CDMO Product Solution and Service
3.7 Date of Enter into Pharmaceutical Intermediate CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical Intermediate CDMO Breakdown Data by Type
4.1 Global Pharmaceutical Intermediate CDMO Historic Market Size by Type (2018-2023)
4.2 Global Pharmaceutical Intermediate CDMO Forecasted Market Size by Type (2024-2029)
5 Pharmaceutical Intermediate CDMO Breakdown Data by Application
5.1 Global Pharmaceutical Intermediate CDMO Historic Market Size by Application (2018-2023)
5.2 Global Pharmaceutical Intermediate CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical Intermediate CDMO Market Size (2018-2029)
6.2 North America Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023)
6.4 North America Pharmaceutical Intermediate CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical Intermediate CDMO Market Size (2018-2029)
7.2 Europe Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023)
7.4 Europe Pharmaceutical Intermediate CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size (2018-2029)
8.2 Asia-Pacific Pharmaceutical Intermediate CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical Intermediate CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical Intermediate CDMO Market Size (2018-2029)
9.2 Latin America Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023)
9.4 Latin America Pharmaceutical Intermediate CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size (2018-2029)
10.2 Middle East & Africa Pharmaceutical Intermediate CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cambrex
11.1.1 Cambrex Company Detail
11.1.2 Cambrex Business Overview
11.1.3 Cambrex Pharmaceutical Intermediate CDMO Introduction
11.1.4 Cambrex Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.1.5 Cambrex Recent Development
11.2 WR Grace
11.2.1 WR Grace Company Detail
11.2.2 WR Grace Business Overview
11.2.3 WR Grace Pharmaceutical Intermediate CDMO Introduction
11.2.4 WR Grace Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.2.5 WR Grace Recent Development
11.3 Esteve Química
11.3.1 Esteve Química Company Detail
11.3.2 Esteve Química Business Overview
11.3.3 Esteve Química Pharmaceutical Intermediate CDMO Introduction
11.3.4 Esteve Química Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.3.5 Esteve Química Recent Development
11.4 AGC Pharma Chemicals
11.4.1 AGC Pharma Chemicals Company Detail
11.4.2 AGC Pharma Chemicals Business Overview
11.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Introduction
11.4.4 AGC Pharma Chemicals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.4.5 AGC Pharma Chemicals Recent Development
11.5 Evonik
11.5.1 Evonik Company Detail
11.5.2 Evonik Business Overview
11.5.3 Evonik Pharmaceutical Intermediate CDMO Introduction
11.5.4 Evonik Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.5.5 Evonik Recent Development
11.6 CordenPharma
11.6.1 CordenPharma Company Detail
11.6.2 CordenPharma Business Overview
11.6.3 CordenPharma Pharmaceutical Intermediate CDMO Introduction
11.6.4 CordenPharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.6.5 CordenPharma Recent Development
11.7 Otsuka Chemical
11.7.1 Otsuka Chemical Company Detail
11.7.2 Otsuka Chemical Business Overview
11.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Introduction
11.7.4 Otsuka Chemical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.7.5 Otsuka Chemical Recent Development
11.8 Wavelength
11.8.1 Wavelength Company Detail
11.8.2 Wavelength Business Overview
11.8.3 Wavelength Pharmaceutical Intermediate CDMO Introduction
11.8.4 Wavelength Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.8.5 Wavelength Recent Development
11.9 KBI Biopharma
11.9.1 KBI Biopharma Company Detail
11.9.2 KBI Biopharma Business Overview
11.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Introduction
11.9.4 KBI Biopharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.9.5 KBI Biopharma Recent Development
11.10 Chengda Pharmaceuticals
11.10.1 Chengda Pharmaceuticals Company Detail
11.10.2 Chengda Pharmaceuticals Business Overview
11.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Introduction
11.10.4 Chengda Pharmaceuticals Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.10.5 Chengda Pharmaceuticals Recent Development
11.11 Apeloa Pharmaceutical
11.11.1 Apeloa Pharmaceutical Company Detail
11.11.2 Apeloa Pharmaceutical Business Overview
11.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
11.11.4 Apeloa Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.11.5 Apeloa Pharmaceutical Recent Development
11.12 Xi'an Manareco New Materials
11.12.1 Xi'an Manareco New Materials Company Detail
11.12.2 Xi'an Manareco New Materials Business Overview
11.12.3 Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Introduction
11.12.4 Xi'an Manareco New Materials Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.12.5 Xi'an Manareco New Materials Recent Development
11.13 Shenzhen Sungening Bio-technology
11.13.1 Shenzhen Sungening Bio-technology Company Detail
11.13.2 Shenzhen Sungening Bio-technology Business Overview
11.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Introduction
11.13.4 Shenzhen Sungening Bio-technology Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.13.5 Shenzhen Sungening Bio-technology Recent Development
11.14 Chengdu D-innovation Pharmaceutical
11.14.1 Chengdu D-innovation Pharmaceutical Company Detail
11.14.2 Chengdu D-innovation Pharmaceutical Business Overview
11.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Introduction
11.14.4 Chengdu D-innovation Pharmaceutical Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.14.5 Chengdu D-innovation Pharmaceutical Recent Development
11.15 Huateng Pharma
11.15.1 Huateng Pharma Company Detail
11.15.2 Huateng Pharma Business Overview
11.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Introduction
11.15.4 Huateng Pharma Revenue in Pharmaceutical Intermediate CDMO Business (2018-2023)
11.15.5 Huateng Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
